These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15582280)

  • 21. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
    Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
    J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid.
    Kanninen K; Malm TM; Jyrkkänen HK; Goldsteins G; Keksa-Goldsteine V; Tanila H; Yamamoto M; Ylä-Herttuala S; Levonen AL; Koistinaho J
    Mol Cell Neurosci; 2008 Nov; 39(3):302-13. PubMed ID: 18706502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
    Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
    J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogold labeling and X-ray fluorescence microscopy reveal enrichment ratios of Cu and Zn, metabolism of APP and amyloid-β plaque formation in a mouse model of Alzheimer's disease.
    Wang H; Wang M; Wang B; Li M; Chen H; Yu X; Yang K; Chai Z; Zhao Y; Feng W
    Metallomics; 2012 Oct; 4(10):1113-8. PubMed ID: 22992540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
    Venti A; Giordano T; Eder P; Bush AI; Lahiri DK; Greig NH; Rogers JT
    Ann N Y Acad Sci; 2004 Dec; 1035():34-48. PubMed ID: 15681799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
    Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
    Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
    Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
    Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice.
    Malm TM; Koistinaho M; Pärepalo M; Vatanen T; Ooka A; Karlsson S; Koistinaho J
    Neurobiol Dis; 2005 Feb; 18(1):134-42. PubMed ID: 15649704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fermented papaya preparation attenuates beta-amyloid precursor protein: beta-amyloid-mediated copper neurotoxicity in beta-amyloid precursor protein and beta-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells.
    Zhang J; Mori A; Chen Q; Zhao B
    Neuroscience; 2006 Nov; 143(1):63-72. PubMed ID: 16962711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome.
    Abrahamson EE; Ikonomovic MD; Ciallella JR; Hope CE; Paljug WR; Isanski BA; Flood DG; Clark RS; DeKosky ST
    Exp Neurol; 2006 Feb; 197(2):437-50. PubMed ID: 16300758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
    Cherny RA; Barnham KJ; Lynch T; Volitakis I; Li QX; McLean CA; Multhaup G; Beyreuther K; Tanzi RE; Masters CL; Bush AI
    J Struct Biol; 2000 Jun; 130(2-3):209-16. PubMed ID: 10940226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
    Mancino AM; Hindo SS; Kochi A; Lim MH
    Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detecting bioactive amyloid beta peptide species in Alzheimer's disease.
    Liu Y; Dargusch R; Banh C; Miller CA; Schubert D
    J Neurochem; 2004 Nov; 91(3):648-56. PubMed ID: 15485495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redox-active metals, oxidative stress, and Alzheimer's disease pathology.
    Huang X; Moir RD; Tanzi RE; Bush AI; Rogers JT
    Ann N Y Acad Sci; 2004 Mar; 1012():153-63. PubMed ID: 15105262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Youdim MB; Fridkin M
    ACS Chem Biol; 2010 Jun; 5(6):603-10. PubMed ID: 20455574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.